850793-25-8Relevant articles and documents
Derivatives of m-Guaiacol, Their Preparation and Their Uses
-
Paragraph 0125; 0138, (2021/11/05)
The invention concerns derivatives of m-guaiacol, their preparation and their uses as biocides, in particular as antibacterials or disinfectants.
PROTEIN KINASE INHIBITORS
-
Paragraph 0173, (2015/07/15)
The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.
Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses
Su, Dai-Shi,Lim, John J.,Tinney, Elizabeth,Wan, Bang-Lin,Young, Mary Beth,Anderson, Kenneth D.,Rudd, Deanne,Munshi, Vandna,Bahnck, Carolyn,Felock, Peter J.,Lu, Meiquing,Lai, Ming-Tain,Touch, Sinoeun,Moyer, Gregory,DiStefano, Daniel J.,Flynn, Jessica A.,Liang, Yuexia,Sanchez, Rosa,Perlow-Poehnelt, Rebecca,Miller, Mike,Vacca, Joe P.,Williams, Theresa M.,Anthony, Neville J.
experimental part, p. 7163 - 7169 (2010/06/16)
Biaryl ethers were recently reported as potent NNRTIs. Herein we disclose a detailed SAR study that led to the biaryl ether 6. This compound possessed excellent potency against WT RT and key clinically observed RT mutants and had an excellent pharmacokinetic profile in rats, dogs, and rhesus macaques. The compound also exhibited a clean safety profile in preclinical safety studies.